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Summary
Background: We conducted a prospective multicenter case—control study to conﬁrmHeart failure;
Treatment
the clinical efﬁcacy and safety of Waon therapy on chronic heart failure (CHF).
Methods: Patients (n = 188) with CHF were treated with standard therapy for at least
1 week, and then were randomized to Waon therapy (n = 112) or a control group
(n = 76). All patients continued conventional treatment for an additional 2 weeks.
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The Waon therapy group was treated daily with a far infrared-ray dry sauna at 60 ◦C
for 15min and then kept on bed rest with a blanket for 30min for 2 weeks. Chest
radiography, echocardiography, and plasma levels of brain natriuretic peptide (BNP)
were measured before and 2 weeks after treatment.
Results: NYHA functional class signiﬁcantly decreased after 2 weeks of treat-
ment in both groups. Chest radiography also showed a signiﬁcant decrease of
the cardiothoracic ratio in both groups (Waon therapy: 57.2± 8.0% to 55.2± 8.0%,
p < 0.0001; control: 57.0± 7.7% to 56.0± 7.1%, p < 0.05). Echocardiography demon-
strated that left ventricular diastolic dimension (LVDd), left atrial dimension
(LAD), and ejection fraction (EF) signiﬁcantly improved in the Waon therapy group
(LVDd: 60.6± 7.6 to 59.1± 8.4mm, p < 0.0001; LAD: 45.4± 9.3mm to 44.1± 9.4mm,
p < 0.05; EF: 31.6± 10.4% to 34.6± 10.6%, p < 0.0001), but not in the control group
(LVDd: 58.4± 10.3mm to 57.9± 10.4mm; LAD: 46.3± 9.7mm to 46.2± 10.1mm;
EF: 36.6± 14.1% to 37.3± 14.0%). The plasma concentration of BNP signiﬁcantly
decreased with Waon therapy, but not in the control group (Waon: 542± 508 pg/ml to
394± 410 pg/ml, p < 0.001; control: 440± 377 pg/ml to 358± 382 pg/ml).
Conclusion: Waon therapy is safe, improves clinical symptoms and cardiac function,
and decreases cardiac size in CHF patients. Waon therapy is an innovative and promis-
ing therapy for patients with CHF.
Natriuretic peptides;
Brain;
Non-pharmacological
therapy
of Cardiology. Published by Elsevier Ireland Ltd. All rights
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Introduction
Chronic heart failure (CHF) is a major and growing
public health problem in Japan, as in other devel-
oped countries. Drugs that interfere with excessive
activation of the rennin—angiotensin—aldosterone
system can relieve the symptoms of heart fail-
ure in patients with a depressed ejection fraction
(EF) by stabilizing and/or reversing cardiac remod-
eling. Thus, angiotensin-converting enzyme (ACE)
inhibitors, angiotensin II receptor blockers (ARBs),
and  blockers have emerged as cornerstones of
modern heart failure therapy for patients with a
depressed EF [1]. Angiotensin II plays an impor-
tant role in the pathogenesis of CHF, and many
large clinical trials have demonstrated the bene-
ﬁts of ACE inhibitors [2,3], and ARBs [4—8] on the
morbidity and mortality of CHF. However, the num-
ber of heart failure deaths has increased steadily
despite advances in treatment, in part, because of
increasing numbers of patients with CHF due to bet-
ter treatment and salvage of patients with acute
myocardial infarction earlier in life [9].
We developed a form of thermal therapy that dif-
fers from the traditional sauna [10], and have been
investigating the effects of thermal therapy since
1989. We discovered that the new thermal ther-
apy offers prominent beneﬁcial effects for patients
with CHF [10—13] and peripheral artery disease
[14,15]. Thermal therapy at very high tempera-
ture was originally used to treat localized cancer.
t
p
ﬁ
oowever, the therapy we developed to treat car-
iovascular diseases is quite different, in that it
onsists of systemic soothing warmth that comfort-
bly refreshes the mind and body. Therefore, we
ave changed the name from thermal, to ‘‘Waon’’
herapy, since ‘‘Waon’’ in Japanese means soothing
armth [16]. Waon therapy is deﬁned as ‘‘therapy
n which the entire body is warmed in an evenly
eated chamber for 15min at a temperature that
oothes the mind and body, and after the deep-
ody temperature has increased by approximately
.0—1.2 ◦C, the soothing warmth is sustained by
aintaining the warmth at rest for an additional
0min, with ﬂuids supplied at the end to replace
he loss from perspiration’’ [16]. We have reported
hat Waon therapy, the repeated use of a dry sauna
t 60 ◦C, improves hemodynamics and ameliorates
ymptoms, suppresses ventricular arrhythmias, and
mproves vascular function in CHF patients [10—13].
e have already performed Waon therapy in sev-
ral hundred CHF patients in our hospital without
ny severe adverse effects.
In order to expand the use of Waon therapy,
e developed a movable and sitting-position sauna
ystem, in which the temperature at the top and
ottom of the chamber is uniformly maintained
t the same temperature of 60 ◦C (Fig. 1). Using
his sitting-position sauna system, we conducted a
rospective multicenter case—control study to con-
rm the clinical effect and safety of Waon therapy
n CHF at 10 different hospitals.
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Culticenter study of Waon therapy for CHF
ubjects and methods
ubjects
en hospitals participated in this multicenter study:
agoshima University Hospital, Kitasato University
ospital, Sakakibara Memorial Hospital, Yamaguchi
niversity Hospital, Juntendo University Hospi-
al, Tokyo Women’s Medical University Hospital,
oranomon Hospital, Higashisumiyoshi Morimoto
ospital, Saiseikai Kumamoto Hospital, and Fuji-
oto Hayasuzu Hospital. We enrolled 188 patients
ith CHF, aged 26—94 years (mean age: 64.7± 13.7
ears). 94 patients had idiopathic dilated car-
iomyopathy, 45 had ischemic cardiomyopathy, 16
atients had valvular heart disease, and 33 patients
ad other heart disease (7 hypertensive heart dis-
ase, 10 hypertrophic cardiomyopathy, 4 dilated
ypertrophic cardiomyopathy, 3 cardiac sarcoido-
is, 3 restrictive cardiomyopathy, 2 atrial septal
efect, 1 cardiac amyloidosis, 1 drug-induced car-
iomyopathy, 1 alcoholic cardiomyopathy, and 1
eft ventricular noncompaction).
Inclusion criteria were the presence of symp-
omatic CHF, left ventricular ejection fraction
LVEF) <50% on echocardiography, and New York
eart Association (NYHA) functional classes II—IV.
xclusion criteria were the presence of severe aor-
ic stenosis, severe obstruction with hypertrophic
bstructive cardiomyopathy, and high fever due to
nfectious disease. Informed consent was obtained
rom all of the patients before participation. This
rotocol was approved by the Ethics Committee of
he Faculty of Medicine, Kagoshima University.
esign of the study protocol
ll patients could receive any kind of medication
or CHF and doctors also could change the medi-
ation during the study. The subjects were treated
ith conventional therapy for at least 1 week, and
hen were randomized to the Waon therapy group
r a control group at each hospital. The patients in
he Waon therapy group received thermal therapy
aily, 5 days a week, for 2 weeks. The patients in
he control group continued the conventional treat-
ent for 2 more weeks.
aon therapyaon therapy uses a far infrared-ray dry sauna,
hich is evenly maintained at 60 ◦C and differs from
raditional sauna. Waon therapy has an absence
f hydration pressure, and was performed as pre-
iously reported [10]. Brieﬂy, the patients were
T
f
m
b
digure 1 Movable and sitting-position sauna system. The
emperature at the top and bottom of the chamber is
niformly maintained at the same temperature of 60 ◦C.
laced in a sitting-position in a 60 ◦C sauna system
or 15min, and then after leaving the sauna, they
nderwent bed rest with a blanket to keep them
arm for an additional 30min. All patients were
eighed before and after the therapy, and oral
ydration with water was used to compensate for
eight lost due to perspiration. Waon therapy was
erformed once a day, 5 days a week for 2 weeks,
or a total of 10 sessions. To rule out any acute
ffects of Waon therapy, all examinations were per-
ormed before the ﬁrst treatment and on the next
ay after the last treatment.
easurements
hysical examination
he blood pressure (BP), pulse rate, body weight,
nd body temperature were measured before and
weeks after treatment.
ardiac functionhe clinical state of CHF was evaluated by NYHA
unctional class. Before and 2 weeks after treat-
ent, the cardiothoracic ratio (CTR) was measured
y chest radiography and left ventricular diastolic
imension (LVDd), left atrial dimension (LAD), and
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VEF were evaluated by conventional echocardiog-
aphy.
aboratory measurements
fasting blood sample was obtained in the morning
o measure the plasma concentrations of the brain
atriuretic peptide (BNP) with radioimmunoassay,
efore and 2 weeks after treatment.
tatistical analysis
ll data are expressed as the mean value± S.D. Dif-
erences in baseline characteristics were evaluated
y a 2 test and unpaired t-test. The data before
nd 2 weeks after treatment were compared using
paired t-test. A p-value of <0.05 was considered
tatistically signiﬁcant.
esults
aseline clinical characteristics
he baseline clinical characteristics are sum-
arized in Table 1. There were no signiﬁcant
ifferences in age, gender, causative heart disease,
YHA functional class, body weight, heart rate, sys-
olic BP (SBP), or diastolic BP (DBP) at baseline
etween the two groups.
linical ﬁndings and physical examinations
uring the study, none of the patients treated with
aon therapy had worsened clinical symptoms. The
hanges in the clinical ﬁndings and variables after 2
eeks are summarized in Table 1. NYHA functional
lass, SBP, and DBP signiﬁcantly decreased in both
roups. Body weight signiﬁcantly decreased in the
aon therapy group, but not in the control group.
here were no signiﬁcant changes in heart rate in
ither group.
hest radiography and echocardiography
ig. 2 shows the results of chest radiography and
chocardiography. Chest radiography showed a
igniﬁcant decrease of the CTR after 2 weeks of
reatment in both groups (Waon therapy group:
7.2± 8.0% to 55.2± 8.0%, p < 0.0001; control
roup: 57.0± 7.7% to 56.0± 7.1%, p < 0.05). In addi-
ion, echocardiography demonstrated that LVDd,
AD, and LVEF signiﬁcantly improved after Waon
herapy (LVDd: 60.6± 7.6mm to 59.1± 8.4mm,
< 0.0001; LAD: 45.4± 9.3mm to 44.1± 9.4mm,
Multicenter study of Waon therapy for CHF 83
Figure 2 Data from chest radiography and echocardiography. Chest radiography showed a signiﬁcant decrease of the
cardiothoracic ratio (CTR) after 2 weeks of treatment in both groups. Echocardiography demonstrated that left ventric-
ular diastolic dimension (LVDd), left atrial dimension (LAD), and left ventricular ejection fraction (LVEF) signiﬁcantly
d hange after 2 weeks of conventional therapy in the control
g osed bars show baseline and open bars indicate values after
2
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Figure 3 Changes in plasma concentration of BNP. The
plasma concentration of BNP signiﬁcantly decreased after
2 weeks of Waon therapy, but did not change in the
control group. *p < 0.001 vs. baseline. Closed bars show
b
tecreased after 2 weeks of Waon therapy, but did not c
roup. *p < 0.05 vs. baseline; **p < 0.0001 vs. baseline. Cl
weeks of treatment.
< 0.05; LVEF: 31.6± 10.4% to 34.6± 10.6%,
< 0.0001), but did not change in the control group
LVDd: 58.4± 10.3mm to 57.9± 10.4mm, not
igniﬁcant; LAD: 46.3± 9.7mm to 46.2± 10.1mm,
ot signiﬁcant; LVEF: 36.6± 14.1% to 37.3± 14.0%,
ot signiﬁcant).
lasma levels of BNP
ig. 3 shows the changes in plasma concentration of
NP. The plasma concentration of BNP signiﬁcantly
ecreased after 2 weeks of Waon therapy, while it
id not change in the control group (Waon ther-
py group: 542± 508 pg/ml to 394± 410 pg/ml,
< 0.001; control group: 440± 377 pg/ml to
58± 382 pg/ml, not signiﬁcant).
iscussion
e developed the sitting-position sauna sys-
em, and conducted a prospective multicenter
ase—control study to conﬁrm the clinical efﬁ-
acy and safety of Waon therapy on CHF at 10
ospitals. In this study, we conﬁrmed that Waon
herapy improved clinical symptoms and cardiac
unction evaluated by echocardiography and BNP
oncentrations, and decreased cardiac size on chest
r
W
s
saseline and open bars indicate values after 2 weeks of
reatment.
adiography and echocardiography after 2 weeks of
aon therapy in patients with CHF. We also demon-
trated that our movable and sitting-position sauna
ystem is effective and safe for patients with CHF.
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Regarding the acute effect of Waon therapy,
we have reported that 60 ◦C sauna therapy for
15min improved acute hemodynamics in patients
with CHF, including cardiac index, mean pulmonary
wedge pressure, systemic and pulmonary resis-
tance, and cardiac function [10]. Subsequently, we
examined the chronic effects of repeated Waon
therapy on clinical symptoms and cardiac func-
tion in patients with CHF and have reported that
4 weeks of Waon therapy signiﬁcantly improved
clinical symptoms, increased ejection fraction, and
decreased cardiac size on the echocardiogram and
chest X-ray [10,11]. Furthermore, we demonstrated
that daily Waon therapy for 2 weeks decreased
ventricular premature contractions and increased
heart rate variability (SDNN, standard deviation of
normal-to-normal beat interval) in patients with
CHF, suggesting that Waon therapy decreased sym-
pathetic nervous activity and improved ventricular
arrhythmias [13].
We then investigated the vascular endothelial
function to clarify the mechanisms of the effect
of Waon therapy on CHF, since vascular endothe-
lial function had been reported to be impaired in
CHF. We have reported that 2 weeks of Waon ther-
apy signiﬁcantly reduced BNP concentrations and
improved endothelial function in patients with CHF.
There was a signiﬁcant correlation between the
change in %FMD (ﬂow-mediated dilatation) and the
percent improvement in BNP concentrations in the
Waon therapy group [12].
In order to conﬁrm the effect of Waon therapy
on CHF and clarify its mechanism, we performed
experimental studies using TO-2 cardiomyopathic
hamsters with heart failure. We reported that the
repeated Waon therapy improved survival in TO-2
cardiomyopathic hamsters with heart failure [17].
We clariﬁed that one of the molecular mecha-
nisms by which repeated Waon therapy improved
endothelial function was an increase in mRNA
and protein of endothelial nitric oxide synthase
(eNOS) in Syrian golden hamsters [18] and TO-2 car-
diomyopathic hamsters [19]. We believe that eNOS
up-regulation induced by repeated Waon therapy is
caused by an increase in cardiac output and blood
ﬂow, which in turn results in increased shear stress,
although thermal stimulation might up-regulate
arterial eNOS directly.
Compared to pharmacological vasodilator ther-
apy and other non-pharmacological therapy, such
as cardiac resynchronization therapy and physi-
cal therapy, there are several advantages of Waon
therapy for CHF. First, it is quite safe and has no
adverse effects. Second, it is less expensive and
more cost-effective. Third, unlike physical therapy,
patients who are elderly or have severe congestive
s
W
D
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eart failure, uncontrolled ventricular arrhythmias,
nd orthopedic limitations are not exempt from
ndergoing Waon therapy. Fourth, this treatment
romotes mental and physical relaxation. Waon
herapy may thus be a valuable adjunct to phar-
acological or non-pharmacological intervention in
he management of CHF.
We have treated many CHF patients with Waon
herapy, and none of the patients so far has shown
ny deterioration in their condition. However, Waon
herapy does not appear to be indicated for CHF
atients with severe aortic stenosis or obstructive
ypertrophic cardiomyopathy, because the pressure
radient might be increased during Waon therapy.
atients with infectious disease are also excluded
rom Waon therapy.
tudy limitations
e have already reported that repeated Waon
herapy improved the prognosis of TO-2 cardiomy-
pathic hamsters with CHF, suggesting a new
otential non-pharmacologic therapy for CHF [17].
he ultimate goal of treatment is the improvement
f prognosis and quality of life. Therefore, we must
valuate the effect of Waon therapy on progno-
is, as well as quality of life, in patients with CHF.
e are conducting a prospective clinical random-
zed study to assess the impact of Waon therapy on
he rate of cardiac death or re-hospitalization in
atients with CHF.
onclusion
n this prospective multicenter study, we conﬁrmed
hat Waon therapy is quite safe, improved clini-
al symptoms and cardiac function, and decreased
ardiac size in patients with CHF. Therefore, Waon
herapy is an innovative and promising therapy for
atients with CHF.
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